Author:
Rieser Nathalie M.,Gubser Ladina P.,Moujaes Flora,Duerler Patricia,Lewis Candace R.,Michels Lars,Vollenweider Franz X.,Preller Katrin H.
Abstract
AbstractResearch into the use of psilocybin for the treatment of psychiatric disorders is a growing field. Nevertheless, robust brain–behavior relationships linking psilocybin-induced brain changes to subjective drug-induced effects have not been established. Furthermore, it is unclear if the acute neural effects are dependent on individual heterogeneity in baseline characteristics. To address this, we assessed the effects of three oral doses of psilocybin vs. placebo on cerebral blood flow (CBF) using arterial spin labeling in healthy participants (N = 70; n = 31, 0.16 mg/kg; n = 10, 0.2 mg/kg; n = 29, 0.215 mg/kg). First, we quantified psilocybin-induced changes in relative and absolute CBF. Second, in an exploratory analysis, we assessed whether individual baseline characteristics and subjective psychedelic experience are associated with changes in CBF. Psychological and neurobiological baseline characteristics correlated with the psilocybin-induced reduction in relative CBF and the psilocybin-induced subjective experience. Furthermore, the psilocybin-induced subjective experience was associated with acute changes in relative and absolute CBF. The results demonstrated that inter-individual heterogeneity in the neural response to psilocybin is associated with baseline characteristics and shed light on the mechanisms underlying the psychedelic-induced altered state. Overall, these findings help guide the search for biomarkers, paving the way for a personalized medicine approach within the framework of psychedelic-assisted therapy.
Funder
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Heffter Young Investigator Fellowship Award
Heffter Research Institute
Swiss Neuromatrix Foundation
Publisher
Springer Science and Business Media LLC
Reference81 articles.
1. Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9, 3897 (1998).
2. Preller, K. H. & Vollenweider, F. X. Phenomenology, structure, and dynamic of psychedelic states. Curr. Top. Behav. Neurosci. 36, 221–256 (2018).
3. Beliveau, V. et al. A high-resolution in vivo atlas of the human brain’s serotonin system. J. Neurosci. 37, 120–128 (2017).
4. Nichols, D. E. & Nichols, C. D. Serotonin receptors. Chem. Rev. 108, 1614–1641 (2008).
5. Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., ... & Malievskaia, E. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Eng. J. Med., 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443 (2022).